EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseVergleichsstudie

Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

Nuttaya Wachiraphansakul iD, Thanawat Vongchaiudomchoke iD, Worapaka Manosroi iD, Chidchanok Ruengorn iD, Kajohnsak Noppakun iD, Tanun Ngamvichchukorn iD, Manish M Sood iD, Kednapa Thavorn iD, Brian Hutton iD, Surapon Nochaiwong iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70884 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Nuttaya Wachiraphansakul und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Lampang Hospital, Lampang, Thailand. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Body Composition, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Chiang Mai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the effects of individual glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on direct body composition among adults with overweight or obesity, with or without type 2 diabetes (T2D).

Methods

We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP‐1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D, without language restrictions. The main outcomes included total body fat (%), fat mass (kg), visceral adipose tissue (VAT) area (cm 2 ), subcutaneous adipose tissue (SAT) area (cm 2 ), liver fat content (%), total lean tissue (%) and lean mass (kg). A frequentist network meta‐analysis was employed using a random‐effects model and reported as standardised mean differences (SMDs). Certainty of evidence was appraised using the Confidence in Network Meta‐Analysis.

Results

We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group. Regarding variations in treatment benefits on body composition, GLP‐1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline. No significant differences for change in total lean tissue were observed. However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg—weekly and tirzepatide 15 mg—weekly (SMDs ranged from −1.09 to −0.50) significantly decreased lean mass from baseline.

Conclusions

GLP‐1RAs substantially improve body composition‐related excess adiposity, but unfavourable effects on lean mass were observed, particularly at high doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Body CompositionGlucagon-Like Peptide-1 Receptor AgonistsObesityOverweightHypoglycemic AgentsHumansRandomized Controlled Trials as TopicSemaglutideTirzepatideLiraglutideAdult

Stichwörter der Autor:innen

body compositionfat distributionglucagon‐like peptide‐1muscle massobesityoverweight

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutideTirzepatideLiraglutide

Autor:innen und Institutionen

  • Department of Internal Medicine, Lampang Hospital, Lampang, Thailand.
  • Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
  • Pharmacoepidemiology and Statistical Research Center (PESRC), Chiang Mai University, Chiang Mai, Thailand.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Division of Nephrology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

ORCID-Profile: Nuttaya Wachiraphansakul, Thanawat Vongchaiudomchoke, Worapaka Manosroi, Chidchanok Ruengorn, Kajohnsak Noppakun, Tanun Ngamvichchukorn, Manish M Sood, Kednapa Thavorn, Brian Hutton, Surapon Nochaiwong

Förderung

  • Chiang Mai University

Zitieren

APA

Wachiraphansakul, N., Vongchaiudomchoke, T., Manosroi, W., Ruengorn, C., Noppakun, K., Ngamvichchukorn, T., Sood, M. M., Thavorn, K., Hutton, B., & Nochaiwong, S. (2026). Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70884

Vancouver

Wachiraphansakul N, Vongchaiudomchoke T, Manosroi W, Ruengorn C, Noppakun K, Ngamvichchukorn T, et al. Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70884

BibTeX
@article{Wachiraphansakul2026,
  author = {Wachiraphansakul, Nuttaya and Vongchaiudomchoke, Thanawat and Manosroi, Worapaka and Ruengorn, Chidchanok and Noppakun, Kajohnsak and Ngamvichchukorn, Tanun and Sood, Manish M and Thavorn, Kednapa and Hutton, Brian and Nochaiwong, Surapon},
  title = {Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70884}
}
Kostenlos starten →